Xtx Topco LTD Cel Sci Corp Transaction History

Xtx Topco LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$1.11 - $1.85 $4,033 - $6,722	3,634 Added 22.27%	19,955 $23,000
Q1 2024 May 13, 2024	BUY	$1.63 - $3.08 $26,603 - $50,268	16,321 New	16,321 $31,000
Q2 2022 Aug 15, 2022	SELL	$2.58 - $4.99 $37,345 - $72,230	-14,475 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$3.93 - $7.7 $56,886 - $111,457	14,475 New	14,475 $57,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.